After Hours Summary: AMZN +6.5%, JNPR +5.8%, MSFT +3.9%, GOOG +3.9%, UBNT -15.4%, AMSC -9.4% following earnings/guidance
After Hours Gainers:
Companies trading higher in after hours in reaction to earnings: IMH +24.1%, SIVB +22.4%, GIMO +14.5%, ALGN +7.7%, AMZN +6.5%, QDEL +6.2%, JNPR +5.8%, CPHD +5.1%, SBUX +4.8%, DGII +4.8%, MSFT +3.9%, GOOG +3.9%, NEM +3.2%, QLIK +2.6%, ACTG +2.5%, BGG +2.2%, BAS +2.1%, EW +1.4%, SYA +0.8%, COF +0.5%
Companies trading higher in after hours in reaction to news: LOOK +29.4% (co and Pyxis Tankers announce that Pyxis will become a publicly listed company as a result of the merger between LookSmart and Pyxis' Maritime Technologies subsidiary), DRNA +4.7% (confirmed FDA granted Orphan Drug Designation for DCR-PH1 to treat primary hyperoxaluria type 1), FTR +3.7% (announced filing of a Form 10 Registration Statement regarding the spin-off of its post-acute / skilled nursing facility portfolio), WD +3.1% (to replace ENTR in the S&P SmallCap 600), DNKN +2.5% (to replace RVBD in the S&P MidCap 400), BIOD +2.4% (Rock Springs Capital Management disclosed a 6.99% passive stake in 13G filing), RF +0.8% (announced initiation of its previously disclosed plans to increase its quarterly common stock dividend to $0.06/share from $0.05/share, and launch a $875 million common stock repurchase program)
After Hours Losers:
Companies trading lower in after hours in reaction to earnings: UBNT -15.4%, AWAY -13%, AMSC -9.4%, SPNC -7.9%, CVTI -7.3%, KN -6.5%, MXIM -5.9%, DV -5.5%, NTGR -4.9%, MXWL -4.74%, MTSN -4.3%, RMD -3.9%, ALTR -3.9%, SYNA -3.4%, P -3.2%, MKTO -2.9%, SHOR -2.9%, FSL -2.5%, CBI -2.4%, HBI -2.3%, IPAR -1.9%, TRN -1.7%, N -0.6%
Companies trading lower in after hours in reaction to news: AERI -66.8% (reported results of Phase 3 registration trial (Rocket 1) for Rhopressa, being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; trial did not meet its primary efficacy endpoint), STEM -11.6% (announced proposed public offering of common stock and warrants; size not disclosed), AMSC -9.4% (announced a proposed public offering of common stock; size and price considerations not disclosed), SPNC -7.9% (announced it is accelerating investments in the Stellarex drug-coated balloon angioplasty platform for treatment of Below the Knee peripheral artery disease), LPCN -7.3% (announced proposed public offering of common stock; size and price not disclosed), RMGN -7.2% (filed for ~26.2 mln share common stock offering by selling shareholders), PDLI -3.1% (disclosed that on April 22, 2015, David Montez, Controller and Chief Accounting Officer resigned effective as of May 15, 2015), NLSN -1.8% (announced secondary common stock offering of 20 mln shares on behalf of selling shareholder)